Lipids and non-cardiac vascular disease: A lecture overview

Current Vascular Pharmacology

Volumn 10, Issue 6, 2012, Pages 743-744

  Mikhailidis, Dimitri P ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Abdominal aortic aneurysms; Atherosclerotic renal artery stenosis; Carotid artery disease; Lipids; Peripheral arterial disease; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ABDOMINAL AORTA ANEURYSM; ARTICLE; CAROTID ARTERY DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); CONTRAST INDUCED NEPHROPATHY; DISEASE ASSOCIATION; DYSLIPIDEMIA; HUMAN; KIDNEY ARTERY STENOSIS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RISK FACTOR; VASCULAR DISEASE;

AORTIC ANEURYSM, ABDOMINAL; CAROTID ARTERY DISEASES; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPID METABOLISM; PERIPHERAL ARTERIAL DISEASE; RENAL ARTERY OBSTRUCTION; RISK FACTORS; TREATMENT OUTCOME; VASCULAR DISEASES;

EID: 84870216393     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016112803520693     Document Type: Article

References (18)

1. Liapis CD, Bell PF, Mikhailidis DP, et al. ESVS Guidelines Collaborators; European Society for Vascular Surgery. ESVS Guidelines: Section A--prevention in patients with carotid stenosis. Curr Vasc Pharmacol 2010; 8: 673-81.
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
3. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769-818.
4. Nordon IM, Hinchliffe RJ, Loftus IM, Thompson MM. Pathophysiology and epidemiology of abdominal aortic aneurysms. Nat Rev Cardiol 2011; 8: 92-102.
5. Twine CP, Williams IM. Systematic review and meta-analysis of the effects of statin therapy on abdominal aortic aneurysms. Br J Surg 2011; 98: 346-53.
6. Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg 2007; 45: 645-54.
7. Youssef F, Gupta P, Seifalian AM, et al. The effect of short-term treatment with simvastatin on renal function in patients with peripheral arterial disease. Angiology 2004; 55: 53-62.
8. Momsen AH, Jensen MB, Norager CB, et al. Drug therapy for improving walking distance in intermittent claudication: a systematic review and meta-analysis of robust randomised controlled studies. Eur J Vasc Endovasc Surg 2009; 38: 463-74.
9. Goldstein LB, Amarenco P, Zivin J, et al.; Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators. Statin treatment and stroke outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 2009; 40: 3526-31.
10. Paraskevas KI, Mikhailidis DP, Moore WS, Veith FJ. Optimal contemporary management of symptomatic and asymptomatic carotid artery stenosis. Vascular 2011; 19: 117-20.
11. Amarenco P, Goldstein LB, Sillesen H, et al.; Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators. Coronary heart disease risk in patients with stroke or transient ischemic attack and no known coronary heart disease: findings from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 2010; 41: 426-30.
12. Corriere MA, Edwards MS, Pearce JD, et al. Restenosis after renal artery angioplasty and stenting: incidence and risk factors. J Vasc Surg 2009; 50: 813-9.
13. Paraskevas KI, Giannoukas AD, Mikhailidis DP. Renal function impairment in peripheral arterial disease: an important parameter that should not be neglected. Ann Vasc Surg 2009; 23: 690-9.
14. Paraskevas KI, Veith FJ, Liapis CD, Mikhailidis DP. Perioperative/periprocedural effects of statin treatment for patients undergoing vascular surgery or endovascular procedures: an update. Curr Vasc Pharmacol 2012; in press.
15. Paraskevas KI, Mikhailidis DP, Veith FJ. Optimal statin type and dosage for vascular patients. J Vasc Surg 2011;53:837-44.
16. Tziomalos K, Athyros VG, Mikhailidis DP. Statin discontinuation: an underestimated risk? Curr Med Res Opin 2008; 24: 3059-62.
17. Paraskevas KI, Giannoukas AD, Kotsikoris I, et al. Contrastinduced nephropathy and the vascular patient. Angiology 2010; 61: 721-3.
18. Athyros VG, Tziomalos K, Florentin M, et al. Statin loading in patients undergoing percutaneous coronary intervention for acute coronary syndromes: a new pleiotropic effect? Curr Med Res Opin 2010; 26: 839-42.